Wells Fargo Starts Xenon Pharmaceuticals (XENE) at Overweight, 'De-risked Epilepsy Asset and MDD Free Call Option Next Year'
Tweet Send to a Friend
(Updated - November 28, 2022 6:50 AM EST)
Wells Fargo analyst Mohit Bansal initiates coverage on Xenon Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells Fargo analyst Mohit Bansal initiates coverage on Xenon Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
